Clinical Trials
26 trialsLong-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
National Institutes of Health Clinical Center (CC)
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
GVHD-PTCy
Milton S. Hershey Medical Center
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
University of Kansas Medical Center
HORIZONS
Massachusetts General Hospital
CY-MET-RIC
Nantes University Hospital
PTCYGVHD
University of Nebraska
APTBCy
St. Petersburg State Pavlov Medical University
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
SYMILIS OCT
University of Palermo
GITMO-RELAPSE
IRCCS San Raffaele
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
FRONTJAK-001
Seoul St. Mary's Hospital
MORPHEE
Centre Hospitalier Universitaire de Besancon
TMF-Allo
University Hospital, Clermont-Ferrand
HLA
University of Liege
oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort
The University of Hong Kong
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein